Pharming Group N.V. Research and Development Expense
Pharming Group N.V. (PHAR) reported Research and Development Expense of $100.37 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-02.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-04-02
EUR
| Period end | Research And Development Expense 12 month |
|---|---|
| 2020-12-31 | 33.71M EUR 20-F · filed 2021-04-07 |
| 2019-12-31 | 28.37M EUR 20-F · filed 2021-04-07 |
| 2018-12-31 | 28.88M EUR 20-F · filed 2021-04-07 |
USD
| Period end | Research And Development Expense 12 month |
|---|---|
| 2025-12-31 | $100.37M 20-F · filed 2026-04-02 |
| 2024-12-31 | $83.15M 20-F · filed 2026-04-02 |
| 2023-12-31 | $68.91M 20-F · filed 2026-04-02 |
| 2022-12-31 | $52.53M 20-F · filed 2025-04-03 |
| 2021-12-31 | $70.37M 20-F · filed 2024-04-04 |
| 2020-12-31 | $38.52M 20-F · filed 2023-04-05 |
| 2019-12-31 | $31.79M 20-F · filed 2022-04-06 |